Clinical Laserthermia Systems AB (CLS)

CLS develops tools for use in cancer care and neurosurgery based on two different principles, both with the intention of treating patient conditions as precisely as possible, while reducing or eliminating unpleasant side effects. 

The Company is headquartered in Lund, Sweden, with subsidiaries in Berlin, Germany and in Boston, USA. 
CLS is listed on Nasdaq First North under the stock symbol CLS B.